ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer

Estrogen receptor alpha gene (ESR1) fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for ESR1 fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jonathan T., Gou, Xuxu, Ellis, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276858/
https://www.ncbi.nlm.nih.gov/pubmed/30525098
http://dx.doi.org/10.1080/23723556.2018.1526005
_version_ 1783378080575782912
author Lei, Jonathan T.
Gou, Xuxu
Ellis, Matthew J.
author_facet Lei, Jonathan T.
Gou, Xuxu
Ellis, Matthew J.
author_sort Lei, Jonathan T.
collection PubMed
description Estrogen receptor alpha gene (ESR1) fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for ESR1 fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy to target ESR1 fusion-induced growth.
format Online
Article
Text
id pubmed-6276858
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-62768582019-10-09 ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer Lei, Jonathan T. Gou, Xuxu Ellis, Matthew J. Mol Cell Oncol Author’s Views Estrogen receptor alpha gene (ESR1) fusion transcripts have been identified in breast cancer but their role in breast cancer is not completely understood. Here, we report a causal role for ESR1 fusions in driving both endocrine therapy resistance and metastasis, and describe a therapeutic strategy to target ESR1 fusion-induced growth. Taylor & Francis 2018-10-09 /pmc/articles/PMC6276858/ /pubmed/30525098 http://dx.doi.org/10.1080/23723556.2018.1526005 Text en © 2018 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s Views
Lei, Jonathan T.
Gou, Xuxu
Ellis, Matthew J.
ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title_full ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title_fullStr ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title_full_unstemmed ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title_short ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
title_sort esr1 fusions drive endocrine therapy resistance and metastasis in breast cancer
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276858/
https://www.ncbi.nlm.nih.gov/pubmed/30525098
http://dx.doi.org/10.1080/23723556.2018.1526005
work_keys_str_mv AT leijonathant esr1fusionsdriveendocrinetherapyresistanceandmetastasisinbreastcancer
AT gouxuxu esr1fusionsdriveendocrinetherapyresistanceandmetastasisinbreastcancer
AT ellismatthewj esr1fusionsdriveendocrinetherapyresistanceandmetastasisinbreastcancer

Ejemplares similares